Paxman Inkomsten in het verleden
Verleden criteriumcontroles 3/6
Paxman has been growing earnings at an average annual rate of 32.4%, while the Medical Equipment industry saw earnings growing at 21.2% annually. Revenues have been growing at an average rate of 24.2% per year. Paxman's return on equity is 19.6%, and it has net margins of 11.5%.
Belangrijke informatie
32.4%
Groei van de winst
31.6%
Groei van de winst per aandeel
Medical Equipment Groei van de industrie | 6.2% |
Inkomstengroei | 24.2% |
Rendement op eigen vermogen | 19.6% |
Nettomarge | 11.5% |
Volgende winstupdate | 15 Nov 2024 |
Recente prestatie-updates uit het verleden
Recent updates
Is It Time To Consider Buying Paxman AB (publ) (STO:PAX)?
Oct 22Results: Paxman AB (publ) Beat Earnings Expectations And Analysts Now Have New Forecasts
Aug 24Paxman (STO:PAX) Might Have The Makings Of A Multi-Bagger
Aug 07After Leaping 28% Paxman AB (publ) (STO:PAX) Shares Are Not Flying Under The Radar
Jul 18Even With A 29% Surge, Cautious Investors Are Not Rewarding Paxman AB (publ)'s (STO:PAX) Performance Completely
May 24Does Paxman (STO:PAX) Have A Healthy Balance Sheet?
Dec 23Paxman (STO:PAX) Shareholders Will Want The ROCE Trajectory To Continue
Aug 25Paxman AB (publ) (STO:PAX) Could Be Riskier Than It Looks
Jun 01Does Paxman (STO:PAX) Have A Healthy Balance Sheet?
Nov 20Is Paxman (STO:PAX) A Risky Investment?
Mar 07Paxman (STO:PAX) Is Making Moderate Use Of Debt
Mar 15Are Insiders Buying Paxman AB (publ) (STO:PAX) Stock?
Jan 22Reflecting on Paxman's (STO:PAX) Share Price Returns Over The Last Year
Dec 18Opbrengsten en kosten
Hoe Paxman geld verdient en uitgeeft. Gebaseerd op laatst gerapporteerde winst, op LTM-basis.
Inkomsten en omzetgeschiedenis
Datum | Inkomsten | Inkomsten | G+A Uitgaven | R&D-uitgaven |
---|---|---|---|---|
30 Jun 24 | 248 | 29 | 64 | 0 |
31 Mar 24 | 236 | 24 | 61 | 0 |
31 Dec 23 | 221 | 8 | 59 | 0 |
30 Sep 23 | 208 | 1 | 94 | 0 |
30 Jun 23 | 188 | -2 | 55 | 0 |
31 Mar 23 | 173 | -7 | 53 | 0 |
31 Dec 22 | 157 | -10 | 49 | 0 |
30 Sep 22 | 143 | -2 | 73 | 0 |
30 Jun 22 | 125 | -12 | 70 | 0 |
31 Mar 22 | 111 | -18 | 65 | 0 |
31 Dec 21 | 105 | -13 | 62 | 0 |
30 Sep 21 | 93 | -23 | 61 | 0 |
30 Jun 21 | 87 | -21 | 57 | 0 |
31 Mar 21 | 80 | -22 | 54 | 0 |
31 Dec 20 | 83 | -19 | 54 | 0 |
30 Sep 20 | 90 | -6 | 56 | 0 |
30 Jun 20 | 96 | -1 | 56 | 0 |
31 Mar 20 | 102 | 6 | 58 | 0 |
31 Dec 19 | 96 | 3 | 57 | 0 |
30 Sep 19 | 90 | -4 | 50 | 0 |
30 Jun 19 | 83 | -5 | 49 | 0 |
31 Mar 19 | 75 | -6 | 47 | 0 |
31 Dec 18 | 69 | -7 | 46 | 0 |
30 Sep 18 | 58 | -9 | 37 | 0 |
30 Jun 18 | 50 | -10 | 35 | 0 |
31 Mar 18 | 43 | -9 | 33 | 0 |
31 Dec 17 | 36 | -7 | 31 | 0 |
Kwaliteitswinsten: PAX has high quality earnings.
Groeiende winstmarge: PAX became profitable in the past.
Analyse vrije kasstroom versus winst
Analyse van de winstgroei in het verleden
Winsttrend: PAX has become profitable over the past 5 years, growing earnings by 32.4% per year.
Versnelling van de groei: PAX has become profitable in the last year, making the earnings growth rate difficult to compare to its 5-year average.
Winst versus industrie: PAX has become profitable in the last year, making it difficult to compare its past year earnings growth to the Medical Equipment industry (28.2%).
Rendement op eigen vermogen
Hoge ROE: PAX's Return on Equity (19.6%) is considered low.